Molecular Templates, Inc. (MTEM): Price and Financial Metrics

Molecular Templates, Inc. (MTEM): $1.50

0.03 (+2.04%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add MTEM to Watchlist
Sign Up

MTEM Price/Volume Stats

Current price $1.50 52-week high $9.45
Prev. close $1.47 52-week low $1.40
Day low $1.40 Volume 26,240
Day high $1.54 Avg. volume 53,270
50-day MA $2.73 Dividend yield N/A
200-day MA $5.23 Market Cap 8.06M

MTEM Stock Price Chart Interactive Chart >


Molecular Templates, Inc. (MTEM) Company Bio


Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is based in Austin, Texas.


MTEM Latest News Stream


Event/Time News Detail
Loading, please wait...

MTEM Latest Social Stream


Loading social stream, please wait...

View Full MTEM Social Stream

Latest MTEM News From Around the Web

Below are the latest news stories about MOLECULAR TEMPLATES INC that investors may wish to consider to help them evaluate MTEM as an investment opportunity.

Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update

MT-6402 Dose Escalation (Part A) Head & Neck Patients (N=8) AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the th

Yahoo | November 13, 2023

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors. The Phase 1 study is a multi-center open-lab

Yahoo | November 2, 2023

Molecular Templates to Participate in Upcoming Investor Conferences

AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced participation in the following upcoming investor conferences: UBS Biopharma Conference 2023 Format: One-on-One

Yahoo | November 1, 2023

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer. Dr. Voi possesses more than 35 years of wide-ranging drug development experience. Dr. Voi will begin his new role on October 2, 2023. Dr. Voi joins M

Yahoo | September 28, 2023

Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM)

Molecular Templates Inc. (MTEM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Yahoo | August 25, 2023

Read More 'MTEM' Stories Here

MTEM Price Returns

1-mo -18.92%
3-mo -57.75%
6-mo -75.81%
1-year -76.74%
3-year -98.86%
5-year -98.44%
YTD -59.79%
2023 -24.19%
2022 -91.63%
2021 -58.25%
2020 -32.86%
2019 246.16%

Continue Researching MTEM

Want to see what other sources are saying about Molecular Templates Inc's financials and stock price? Try the links below:

Molecular Templates Inc (MTEM) Stock Price | Nasdaq
Molecular Templates Inc (MTEM) Stock Quote, History and News - Yahoo Finance
Molecular Templates Inc (MTEM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!